The Other Fish In The Sea: AstraZeneca Buys Omthera
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.